The power of patient engagement: A trailblazing journey to elevate access
From incorporating patient insights to enhance understanding and refining trials through stakeholder collaboration for optimal patient outcomes and fair access, there is still much work needed to improve accessibility.
To tackle these challenges effectively, George emphasized the importance of meeting patients where they are and better understanding the journeys and struggles faced by caregivers.
In this landscape, non-therapeutics companies such as technology and services providers, and contract development and manufacturing organizations (CDMOs) play a crucial role in bridging connections between pharmaceutical entities and patients earlier in their healthcare journeys.
“Companies like Cencora can help to build some of those bridges between pharma and advocacy groups to establish multi-stakeholder teams that can get patients the information they need, when they need it,” noted George Eastwood.
Fill out the form below to watch the full recording for deeper insights into enhancing patient support programs, improving data integration, and prioritizing patient-centric approaches in drug development.
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.